The development and clinical validation of a turbulent-flow liquid chromatography-tandem mass spectrometric method for the rapid quantitation of docetaxel in serum.
Docetaxel is a second generation taxane utilized as an anti-neoplastic agent in cancer chemotherapies. Traditional treatment regimens have resulted in significant adverse effects, resulting in the shift to more frequent drug administration at lower doses. As a result, it is important to monitor serum docetaxel concentrations to optimize efficacy and minimize adverse effects. Serum containing docetaxel was combined with acetonitrile containing deuterated internal standard, and following protein precipitation, supernatant was diluted with water for on-line sample extraction. Following turbulent-flow chromatography (TFC), analytic separation was achieved on a Hypersil Gold C-18 (50×2.1mm) column and the eluent analyzed using a TSQ Vantage mass spectrometer with selected reaction monitoring. Matrix effects were characterized in addition to carryover, precision, linearity, recovery and functional sensitivity. The simple and complex precision for the assay at multiple concentrations was ≤6.2%. The assay has functional sensitivity of <3ng/ml, and is linear from 8.1 to 1978ng/ml. Method comparison studies with a reference HPLC-MS/MS method show a slope of 0.84 with a Spearman coefficient of 0.99. Based on the validation metrics, we have generated a sensitive and automated TFC-MS/MS method for docetaxel quantitation in serum.